Onconetix (NASDAQ:ONCO – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.
Risk & Volatility
Onconetix has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Onconetix and Agenus, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
| Agenus | 1 | 1 | 2 | 0 | 2.25 |
Insider & Institutional Ownership
23.9% of Onconetix shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 6.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Onconetix and Agenus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Onconetix | -1,575.89% | -91.95% | -53.76% |
| Agenus | 69.33% | -47.68% | 57.73% |
Valuation and Earnings
This table compares Onconetix and Agenus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Onconetix | $810,000.00 | 3.65 | -$14.03 million | $248.12 | 0.00 |
| Agenus | $114.20 million | 3.19 | $120,000.00 | $2.58 | 3.14 |
Agenus has higher revenue and earnings than Onconetix. Onconetix is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
Summary
Agenus beats Onconetix on 11 of the 14 factors compared between the two stocks.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
About Agenus
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
